Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial
- Effect of Triglycyl--Lysin--Vasopressin on Quantitative Liver Function Tests in Patients with Cirrhosis. Merkel, Carlo; Bianco, Simone; Bolognesi, Massimo; Caregaro, Lorenza; Amodio, Piero; Sacerdoti, David; Gatta, Angelo // American Journal of Gastroenterology;Nov1992, Vol. 87 Issue 11, p1580
The effects of vasopressin and of its analogues on liver function, and their possible mechanisms of action, are poorly understood. This study was designed to assess the effect of triglycyl-lysin-vasopressin on liver function, evaluated by two quantitative tests independent of liver blood flow,...
- Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis. Combes, Burton; Luketic, Velimir A.; Peters, Marion G.; Zetterman, Rowen K.; Garcia-Tsao, Guadalupe; Munoz, Santiago J.; Lin, Danyu; Flye, Nancy; Carithers, Robert L. // American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p264
OBJECTIVE: Randomized, double-blind, placebo-controlled trials of ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) have not demonstrated improvement in survival during the placebo-controlled phases of these trials. Analyses purporting to demonstrate a survival...
- A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. Sharma, Barjesh Chander; Sharma, Praveen; Lunia, Manish Kumar; Srivastava, Siddharth; Goyal, Rohit; Sarin, S K // American Journal of Gastroenterology;Sep2013, Vol. 108 Issue 9, p1458
OBJECTIVES:Hepatic encephalopathy (HE) is associated with poor prognosis in cirrhosis. Drugs used in the treatment of HE are primarily directed at the reduction of the blood ammonia levels. Rifaximin and lactulose have shown to be effective in HE. We evaluated the efficacy and safety of...
- Liver cirrhosis. // Nursing Standard;11/22/2006, Vol. 21 Issue 11, p58
A quiz concerning liver cirrhosis is presented.
- Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients. Weber-Carstens, Steffen; Deja, Maria; Bercker, Sven; Dimroth, Anna; Ahlers, Olaf; Kaisers, Udo; Keh, Didier // Intensive Care Medicine;Apr2007, Vol. 33 Issue 4, p730
To determine whether glycemic control is less feasible when hydrocortisone is given as a bolus compared with continuous application in septic shock patients. Observational prospective pilot study. Fourteen-bed surgical university hospital ICU. Sixteen consecutive patients with septic shock...
- Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrinedependent septic. // Critical Care;2011, Vol. 15 Issue 3, p10453
The article presents a study on the effects of continuously infused norepinephrine (NE) with terlipressin (TP), arginine vasopressin (AVP), or placebo on sublingual microcirculation in septic shock patients. The study uses a prospective, randomized, double-blind clinical trial. Results show that...
- Liver cirrhosis: lobar differences in disease progression and carcinogenesis. Sakon, Masato // Journal of Gastroenterology;2000, Vol. 35 Issue 6, p479
Comments on a study by S. Arjizumi et al on lobar differences in liver disease progression and carcinogenesis. Factors that influence differences in progression of liver cirrhosis among liver segments; Segment where hepatocellular carcinoma occurs frequently; Role of blood flow in hypertrophy...
- Type 1 diabetes associated with chronic liver disease. Taliercio, Adam // Endocrine Today;Dec2012, Vol. 10 Issue 12, p11
The article explores a study on patient with type 1 diabetes' greater risk for developing chronic liver disease, which was concluded by the researchers after they found that 14 type 1 diabetes patients in their study developed cirrhosis.
- Liver I. // Gut;Jun2014 Supplement, Vol. 63, pA87
The article presents abstracts on studies done on liver diseases on topics including reduced amount of serum sodium in patients treated with terlipressin, care in decompensated cirrhosis, and management of patients with decompensated liver disease.